Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma
This article was originally published in PharmAsia News
MUMBAI - News reports of Teva Pharmaceutical Industries Ltd. CEO Shlomo Yanai's recent visit to India sparked rumors that the company may have finally set its sights on the Indian market via a joint venture with Cipla Ltd. But even as the world's largest generic company toys with the idea of entering the sub-continent, leading analysts predict that the next Teva - referencing its multi-fold growth in the last six years - could soon emerge out of India
You may also be interested in...
India’s Sun Pharma Reported Bid For Bausch & Lomb And Meda Raises Hopes For Bigger Buyouts
Sun Pharma has been increasingly linked to a potential global deal in the branded and specialty segments. With former Teva CEO Israel Makov as Sun’s chairman, and robust earnings continuing to pour in, a deal may be just around the corner.
Indian Companies Should Follow Teva Path, With Market-specific Plans, Global Scale – Experts
Rapid global expansion with control on costs may keep Indian drug companies in business. The larger the size the better, say experts from IMS Health and Accenture.
Global Transformation? Sun Pharma Names Former Teva CEO Israel Makov As Chairman
Experts say the Indian pharma’s strategy may be to drive high growth in RoW markets and enable a transition to professional management.